GNBT - Generex Biotechnology Corporation

Other OTC - Other OTC Delayed Price. Currency in USD
18.50
+1.91 (+11.51%)
At close: 3:51PM EST
Stock chart is not supported by your current browser
Previous Close16.59
Open16.31
Bid0.00 x 0
Ask0.00 x 0
Day's Range16.31 - 18.85
52 Week Range1.76 - 25.30
Volume14,778
Avg. Volume12,650
Market Cap25.05M
Beta (3Y Monthly)-9.48
PE Ratio (TTM)4.71
EPS (TTM)3.93
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.00
Trade prices are not sourced from all markets
  • Business Wire3 days ago

    Generex Announces Investor Conference Call; Management to Provide Update on Initiatives & Strategic Plans

    Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that it will hold an investor conference call at 9:00 a.m. Eastern time on Monday, December 3, 2018. Generex President & Chief Executive Officer Joseph Moscato stated: “I will look forward to addressing my fellow stockholders following the November 30 payment of the common stock dividend, along with the rest of the Generex management team, to provide a comprehensive update on your Company’s recent successes and your management team’s near-term and longer-term objectives.

  • Business Wire4 days ago

    Generex Announces Appointment of Executive Management Team

    Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) announced today that, following the successful completion of the recently announced acquisition of the operating assets of the Veneto Group and the establishment of a wholly-owned subsidiary, NuGenerex Distribution Solutions, the Company is now fully operational as a full-service management services organization (MSO) in five states, with an aggressive growth strategy designed to expand the model to an additional 20+ states in the next several months. As part of the integration, several executives from the Veneto Group have joined the executive management team of Generex, providing both a foundation for growth of the MSO model as well as leadership to advance the corporate strategy for the parent company.

  • Business Wire4 days ago

    Generex Revises Record & Payment Dates for 20:1 Stock Dividend

    Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that it has revised the record and payment dates for the previously announced 20:1 common stock dividend. The Record Date for the determination of the holders of the Company’s common stock entitled to participate in the Company’s 20:1 common stock dividend will now be Tuesday, November 20, 2018. The dividend Payment Date will be Friday, November 30, 2018.

  • Business Wire6 days ago

    Generex Publishes Update to Pending 20:1 Stock Dividend

    Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today released an update on its previously announced 20:1 common stock dividend pending completion of FINRA review. All OTC traded companies are required to file a notice with FINRA of material corporate actions such as a stock dividend. Generex did so in the case of the planned stock dividend.

  • Business Wire12 days ago

    Generex Addresses the Opioid Crisis; Provides Proven, Non-Opioid Pain Management Solutions

    Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is addressing the opioid crisis through its affiliate, NuGenerex Distribution Solutions (NDS), providing physicians and patients alternative, non-opioid solutions for post-surgical pain management. Acute post-operative pain is prevalent in virtually all surgical patients.

  • GlobeNewswire13 days ago

    GNBT - Goldman Small Cap Research Issues Research Report on Generex Biotechnology Corp. and Interview with its CEO

    BALTIMORE, Nov. 05, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Generex Biotechnology Corp. (GNBT), an emerging, diversified health care provider, announced today that Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors has released a new research report and CEO interview. The report carries a price target. To view the new research report, listen to the interview, along with viewing disclosures and disclaimers, or to download them in their entirety, please visit http://www.goldmanresearch.com. Generex is a strategic, diversified healthcare holdings company with offerings in a variety of services, diagnostics, medical devices, and pharmaceutical development.

  • ACCESSWIRE14 days ago

    Goldman Small Cap Research Issues Research Report on Generex Biotechnology Corp. and Interview with its CEO

    BALTIMORE, MD / ACCESSWIRE / November 5, 2018 / Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has released a new research report and CEO interview on emerging, diversified health care provider Generex Biotechnology Corp. (GNBT). To view the new research report, listen to the interview, along with viewing disclosures and disclaimers, or to download them in their entirety, please visit http://www.goldmanresearch.com. The Company's direct-to-patient services support its strategy of all-inclusive access to doctors, diagnostics, therapeutics, and additional health-related services to greatly improve the patient experience in receiving care.

  • Business Wire14 days ago

    Generex Announces REVISED Record & Payment Dates for 20:1 Stock Dividend

    Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that it has REVISED the record and payment dates for the previously announced 20:1 common stock dividend. Due to a substantial number of inquiries from investors over the past several days, the Record Date for the determination of the holders of the Company’s common stock entitled to participate in the Company’s 20:1 common stock dividend will now be Friday, November 9, 2018. The dividend Payment Date will be Monday, November 19, 2018.

  • Business Wire17 days ago

    Generex Biotechnology Finalizes Acquisition of Remaining Veneto Operating Assets

    Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that it has completed the second and final tranche of the acquisition of operating assets from Veneto Holdings, L.L.C. (“Veneto”), a private company, and certain of its affiliated entities (collectively, the “Veneto Group”). The Veneto Group provides specialty pharmacy services and products including surgical products and services, diagnostic testing for screening human blood, urine and/or saliva samples for the presence of narcotics, medications, alcohol and other drugs and substances, durable medical equipment services, and ancillary healthcare services such as management services for its businesses.

  • Business Wire18 days ago

    Generex Biotechnology Announces Record & Payment Dates for 20:1 Stock Dividend

    Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that the Record Date for the determination of the holders of the Company’s common stock entitled to participate in the Company’s previously announced 20:1 common stock dividend will be Monday, November 5, 2018. The stock dividend will result in 20 shares of common stock paid on November 13, 2018 for every one share of common stock owned as of the close of business on November 5, 2018. Generex is a strategic, diversified healthcare holdings company with offerings in a variety of services, diagnostics, medical devices, and pharmaceutical development.

  • GlobeNewswire19 days ago

    Scientus Pharma Provides Update on Buccal Cannabis Development Program

    HydRx Farms Ltd. (o/a Scientus Pharma) (“Scientus” or the “Company”), a biopharmaceutical company conducting research and product development for extracts and formulations related to medical cannabinoids and their derivatives, today provided an update on its collaboration with Generex Biotechnology Corporation (GNBT) (“Generex”), whereby the companies are co-developing products for the delivery of cannabinoids via the buccal mucosa (the inner lining of the mouth). Ft. commercial production facility in Whitby, Ontario, the Company will turn its focus towards the final development of a buccal cannabis spray using Generex's RapidMist™ technology.

  • Business Wire21 days ago

    Generex Biotechnology Announces IND Filing for a Phase II Clinical Trial of AE37 in Combination with Pembrolizumab (Keytruda®) for the Treatment of Triple-Negative Breast Cancer

    Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that the Company filed an investigational new drug application (IND) with the U.S. Food & Drug Administration (FDA) to initiate A Phase II Clinical Trial of Pembrolizumab (Keytruda®) in Combination with the AE37 Peptide Vaccine in Patients with Metastatic Triple Negative Breast Cancer. The trial, sponsored by Generex wholly-owned subsidiary Antigen Express, Inc. (www.antigenexpress.com) and conducted in conjunction with research partners Merck and the NSABP Foundation, Inc. (NSABP), is scheduled to initiate sites in the fourth quarter and to begin enrolling patients in the first quarter of 2019.

  • Business Wire28 days ago

    Generex Confirms & Clarifies 20:1 Common Stock Dividend

    Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today confirmed its previously announced plan to issue a 20:1 stock dividend. The announcement today includes a clarification of the stock dividend process and how it is different from a forward spilt. On October 10, 2018 the Company announced that its Board of Directors had approved the issuance of 20 shares of common stock for every one share of issued and outstanding common stock.

  • Business Wirelast month

    Generex Announces Launch of NuGenerex Distribution Solutions

    Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased to announce the launch of NuGenerex Distribution Solutions, and the commencement of business operations enabled through the acquisition of certain operating assets of Veneto Holdings, L.L.C., as announced on October 9, 2018. NuGenerex Distribution Solutions (NDS), an affiliate of Generex, has begun implementing its plan to provide essential management services to an extensive network of top-tier ancillary service providers, including pharmacies, laboratories, diagnostic imaging centers, and durable medical equipment manufacturers. Generex Chief Operating Officer, Terry Thompson, stated, “Generex will be providing centralized insurance adjudication, product procurement, and other support services that allow the acquired assets to increase revenue and service quality, decreasing costs, while focusing on providing better patient care.

  • Business Wirelast month

    Generex Announces Anthony S. Crisci, Esq., CPA as General Manager, Chief Compliance Officer and Corporate Counsel of its New, Wholly-Owned Subsidiary, NuGenerex Distribution Solutions

    Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased to announce that Anthony S. Crisci, Esq., CPA has joined the Company as the General Manager, Chief Compliance Officer & Corporate Counsel for all of NuGenerex’s distribution efforts, including its newly acquired eight (8) pharmacies and laboratory from Veneto Holdings, L.L.C., to lead the Company in building an end-to-end solution for pharmacy and health management services. Mr. Crisci, a member of the New York and New Jersey Bar associations, as well as a licensed CPA, has built a stellar career as a business legal executive across a number of regulated industries.

  • Business Wirelast month

    Generex Announces Stock Dividend

    Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced its plan to issue a stock dividend. The Company’s Board of Directors has approved the issuance of 20 shares of common stock for every one share of issued and outstanding common stock. As at the date hereof, there are 1,068,100 shares of the Company’s common stock issued and outstanding.

  • Business Wirelast month

    Generex Announces Closing of First Tranche Acquisition of Operating Assets

    Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) (“Generex”) today provided further details in respect of its October 3, 2018 acquisition of certain operating assets of Veneto Holdings, L.L.C. (“Veneto”), a private company, and certain of its affiliated entities (collectively, the “Veneto Group”). The Veneto Group is engaged in the business of providing (i) certain specialty pharmacy services and products, (ii) surgical products and services, (iii) diagnostic testing for screening human blood, urine and/or saliva samples for the presence of narcotics, medications, alcohol and other drugs and substances, (iv) durable medical equipment services, and (v) similar ancillary healthcare services such as management services for the foregoing businesses (collectively, the “Business”).

  • Business Wirelast month

    Generex Biotechnology Provides Update on AE37 Immuno-Therapeutic Clinical Development Program

    Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased to announce that the Company, in conjunction with its research collaborators Merck and the NSABP Foundation, will file an IND in October to initiate A Phase II Clinical Trial of Pembrolizumab (Keytruda®) in Combination with the AE37 Peptide Vaccine in Patients with Metastatic Triple Negative Breast Cancer. It is anticipated that the trial will initiate sites in the fourth quarter and begin enrolling patients in the first quarter of 2019.

  • Business Wire2 months ago

    Generex Biotechnology Corporation Shareholder Alert

    Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased to announce that the Company has closed the first tranche of a purchase of the going concern assets of a business providing (i) certain specialty pharmacy services and products, (ii) surgical products and services, (iii) diagnostic testing for screening human blood, urine and/or saliva samples for the presence of narcotics, medications, alcohol and other drugs and substances, (iv) durable medical equipment services, and (v) similar ancillary healthcare services, and the provision of management services for the foregoing businesses. Furthermore, in the same transaction, Generex has committed to closing on the acquisition of additional operating assets within the next 30 days that will significantly enhance revenue and establish a platform for growth that is projected to become a lucrative enterprise through expansion from the three states currently served to an additional 23 states targeted in the expansion plan.

  • Business Wire2 months ago

    Generex Launches NuGenerex Medical Marketing

    Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased to announce the launch of NuGenerex Medical Marketing (NMM) (https://nugenerexmedicalmarketingllc.com/) to provide in-depth patient health management services, including patient identification, acquisition and onboarding, as well as ongoing patient support services for chronic care management through a dedicated call-center. Generex is establishing NMM as an integrated sales and marketing backbone to support the previously announced plan to establish the Company as a presence in the U.S. direct-to-consumer pharmaceuticals business through a multi-channel acquisition strategy.

  • Business Wire2 months ago

    Generex Subsidiary Hema Diagnostic Systems, LLC dba NuGenerex Diagnostics Announces Filing of a European CE Marking Application

    Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that its subsidiary, Hema Diagnostic Systems, LLC dba NuGenerex Diagnostics (www.nugenerexdiagnostics.com), has filed an application for European Economic Area (EEA) CE Marking of its newly developed point-of-care platform, the Express II, in respect of the commercialization of the device for the rapid testing of syphilis antibodies as part of international diagnostic testing algorithms. CE Marking signifies that products sold in the EEA have been assessed to meet high safety, health, and environmental protection requirements and ensures free movement of products within the 30 EEA countries.

  • Business Wire3 months ago

    Generex Biotechnology to Present Overview of Immuno-Oncology Development Program at Summit in Boston, MA

    Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased to announce that Richard Purcell, the Company’s Executive Vice President of Research & Development will participate in a panel discussion at the Cambridge Healthtech Institute’s Immuno-Oncology Summit at the Seaport World Trade Center in Boston, MA (https://www.immuno-oncologysummit.com/) on August 30, 2018. The panel discussion will focus on current trends and future prospects for immunotherapy in the treatment of cancer.

  • Business Wire5 months ago

    Generex Biotechnology Corporation Announces the Filing of a Patent for its New Diagnostic Point-of-Care Platform, the Express II

    Hema Diagnostic Systems, LLC dba NuGenerex Diagnostics (www.hemadiagnosticsystems.com), a subsidiary of Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote), announced today the filing of a patent on its new diagnostic qualitative point-of-care platform, the Express II. Analytes that can be measured by this new device include antigens or antibodies and protein biomarkers which are found in infectious diseases, metabolic diseases and in a host of other medical conditions. The Express II has major advantages over other point-of-care devices because of its simplicity of use, which include fewer steps of operation, the elimination of loops or pipettes for transferring samples, the elimination of unnecessary sample pickup pads, and its ability to be utilized in professional settings, remote field use and for individual in-home use directly by consumers who can conduct the test by themselves in privacy.

  • Business Wire5 months ago

    Generex Announces Terry Thompson as Chief Operating Officer

    Generex Biotechnology Corporation (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased and proud to announce that Terry Thompson has joined the Company’s executive management team as Chief Operating Officer to lead the Company’s efforts in building an end-to-end solution for patients, to include pharmacy, clinical laboratories, pharmacogenomic testing (PGx), compounding, drug manufacturing, and other ancillary health management services. Mr. Thompson brings a wealth of experience and expertise in healthcare, providing executive leadership in pharmacy benefits management, network administration, claims processing, and distribution & logistics for drugs, durable medical equipment (DME), and infusion therapy, as illustrated by his impressive 35-year career.

  • Business Wire10 months ago

    Generex CEO Provides 2017 Year-End Summary to Stakeholders

    Generex Biotechnology Corporation today issued the following letter from the Company’s President & Chief Executive Officer, Joseph Moscato, providing his fellow stockholders with a summary of the Company’s initiatives and achievements over the course of 2017.